Wall Street Zen downgraded First Tracks Biotherapeutics (NASDAQ:TRAX) from Hold to Sell on September 5, 2026. The rating change followed a 4.8% drop in share price. The stock opened at $40.46 on the day of the downgrade.
The company recently reported a quarterly loss of $0.95 per share. This result missed analyst expectations by $0.21. The broader analyst consensus remains a Moderate Buy with an average price target of $63.00.
A September 4 Form 4 filing revealed that Director J. Anthony Ware sold 39,265 shares on September 2. This transaction reduced his direct holdings by over 71%. Several institutional investors recently established new positions in the company.